drugset / Trial / NCT03325322

Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease

NCT03325322

Phase 2 Suspended 30 enrolled Mayo Clinic
RandomizedParallel-groupTriple-blindTreatment

Summary

The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease.

Timeline

Start
2018-01-02
Primary completion
2027-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fisetin Small molecule 20 mg/kg Oral